{"links":{"html":"https://www.erudio.com/reports/acceleret-lung-nct04222972","json":"https://www.erudio.com/reports/acceleret-lung-nct04222972.json","markdown":"https://www.erudio.com/reports/acceleret-lung-nct04222972.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"acceleret-lung-04222972"}},"request":"https://www.erudio.com/contact?report=acceleret-lung-04222972"},"offer":{"cited_commentary_sources":30,"verified_hcp_statements":70,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":11,"optional":true,"price_per_verified_person_usd":15,"price_usd":165,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"acceleret-lung-nct04222972"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=acceleret-lung-04222972","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/acceleret-lung-nct04222972","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-28T15:09:13.855901Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":9,"no_commentary_found":0},"aspects":[{"claim_count":20,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":17,"title":"Primary endpoint: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS)"},{"claim_count":15,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":12,"title":"Secondary endpoints"},{"claim_count":7,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":4,"title":"Population and setting"},{"claim_count":11,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":11,"title":"The comparison"},{"claim_count":30,"coverage":"discussed","id":"T5","registry_field":"outcomesModule","source_count":22,"title":"Safety and tolerability"},{"claim_count":10,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":7,"title":"Design and conduct"},{"claim_count":4,"coverage":"discussed","id":"A1","source_count":4,"title":"Molecular testing before the frontline decision"},{"claim_count":4,"coverage":"discussed","id":"A2","source_count":3,"title":"Alternative selective RET inhibitors and future differentiation"},{"claim_count":2,"coverage":"discussed","id":"A3","source_count":2,"title":"European access and treatment continuity"}],"counts":{"cited_sources":32,"claims_by_expression_type":{"comparison":3,"interpretation":19,"opinion":3,"primary_context":17,"question":2,"restatement":24,"unspecified":2},"claims_by_kind":{"attributed_opinion":12,"limitation":1,"objective_result":1,"protocol_statement":12,"publication_statement":1,"source_observation":43},"clinician_statements":11,"evidence_units":64,"findings":6,"organisational_accounts":5,"people_cited":14,"people_identity_verified":11,"people_total":14,"screened_sources":53,"verified_claims":70},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":19,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":12,"views":6},"has_counterview":true,"limitations":3,"links":{"context":2,"support":22},"ma_question":true,"named_voices":8,"passages":17,"sources":14,"sources_by_kind":{"commentary":12,"media":1,"registry":1}},"title":"Infection-risk mitigation is the most consequential unresolved qualification"},{"id":"F2","structure":{"claims":21,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":8,"views":12},"has_counterview":true,"limitations":3,"links":{"context":1,"support":27},"ma_question":true,"named_voices":8,"passages":17,"sources":16,"sources_by_kind":{"commentary":15,"media":1}},"title":"Favorable frontline positioning rests on disease control, with safety and survival caveats"},{"id":"F3","structure":{"claims":17,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":13,"views":4},"has_counterview":false,"limitations":3,"links":{"context":0,"support":20},"ma_question":true,"named_voices":5,"passages":17,"sources":8,"sources_by_kind":{"commentary":5,"media":1,"publication":1,"registry":1}},"title":"Premature closure and immature OS constrain the evidentiary conclusion"},{"id":"F4","structure":{"claims":9,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":6,"views":2},"has_counterview":false,"limitations":3,"links":{"context":0,"support":10},"ma_question":true,"named_voices":4,"passages":7,"sources":5,"sources_by_kind":{"commentary":3,"media":1,"registry":1}},"title":"Subgroup reassurance is clinically useful but does not erase eligibility boundaries"},{"id":"F5","structure":{"claims":5,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":2,"views":3},"has_counterview":false,"limitations":2,"links":{"context":0,"support":6},"ma_question":true,"named_voices":3,"passages":5,"sources":5,"sources_by_kind":{"commentary":4,"registry":1}},"title":"Molecular testing is framed as part of the frontline treatment decision"},{"id":"F6","structure":{"claims":7,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":3,"views":1},"has_counterview":false,"limitations":3,"links":{"context":0,"support":7},"ma_question":true,"named_voices":2,"passages":6,"sources":5,"sources_by_kind":{"commentary":4,"registry":1}},"title":"Choice among RET inhibitors raises differentiation and European access questions"}],"medical_affairs_question":"How should Medical Affairs explain the favorable frontline disease-control interpretation while preserving the uncertainty around infection-risk mitigation, survival benefit and accessible treatment choice?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Infection-risk mitigation is the most consequential unresolved qualification"},{"id":"section-2","level":2,"title":"Favorable frontline positioning rests on disease control, with safety and survival caveats"},{"id":"section-3","level":2,"title":"Premature closure and immature OS constrain the evidentiary conclusion"},{"id":"section-4","level":2,"title":"Subgroup reassurance is clinically useful but does not erase eligibility boundaries"},{"id":"section-5","level":2,"title":"Molecular testing is framed as part of the frontline treatment decision"},{"id":"section-6","level":2,"title":"Choice among RET inhibitors raises differentiation and European access questions"},{"id":"section-7","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":12},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":4},{"id":"F6","shared_claims":1}],"id":"T1","label":"Primary endpoint: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS)"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":10},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":2},{"id":"F6","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":5}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":6},{"id":"F4","shared_claims":4},{"id":"F6","shared_claims":1}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":18},{"id":"F2","shared_claims":13},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":9},{"id":"F4","shared_claims":3}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-28T15:09:13.855901Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-28T15:23:33Z","record_hash":"5c23d9d4e0ac7f053d6fbfb7712f7748798252435810047a7e0444548bb5ae61","release_hash":"7495d418f81528cc7e06fefc10d46e2be72e19c53218e511e0e6fa0f958143a4","report_id":"erudio-nct04222972","run_id":"f5278581-4b90-4f22-99b3-2f0e295e1077","schema_version":"5.0","slug":"acceleret-lung-04222972","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Clinician commentary on AcceleRET-Lung in the sources reviewed for this edition leads to one open question: How should Medical Affairs explain the favorable frontline disease-control interpretation while preserving the uncertainty around infection-risk mitigation, survival benefit and accessible treatment choice? Its leading findings: (1) infection-risk mitigation is the most consequential unresolved qualification. (2) favorable frontline positioning rests on disease control, with safety and survival caveats. (3) premature closure and immature OS constrain the evidentiary conclusion. 3 more findings follow. 53 sources screened, 32 cited; not all HCPs or all public discussion.","meta_description":"53 sources screened · 70 verified statements (11 from clinicians verified by NPI or staff page) from 32 sources · 6 findings. Updated Oct 28, 2026.","person_names_policy":"role_only","sample_findings":{"reason":"Sample findings are not shown for this edition.","status":"unavailable"}},"publication":{"approved_at":"2026-10-28T15:23:33Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":53},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a remark on sponsor termination and accrual completeness when interpreting first-line pralsetinib evidence.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","19 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition do not represent all HCPs or all public discussion. Repeated summaries and reposts cannot be counted as independent clinical agreement.","Discussion that did not clearly name the trial or used different spellings may be missing. Two passages were not fully assessed, so additional relevant views may be absent.","Only part of the available regulatory material was examined; the safety-alert relays are not a complete assessment of current labeling or all regulatory communications.","No primary publication of the randomized AcceleRET-Lung results is included. The reviewed publication concerns ARROW, a distinct single-arm phase I/II study.","Enrollment descriptions and termination timing differ across sources and have not been reconciled. Source-specific descriptions should not be silently standardized.","Post-amendment infection observations do not establish a causal reduction in mortality or prove that risk was eliminated; trial patients and the separate safety databases must remain distinct.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The sources do not provide a head-to-head ranking of selective RET inhibitors, specific toxicity differences for every alternative, or country-level European access criteria."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"other":0,"podcast":0,"publication":1,"registry":1,"regulatory":0,"x_thread":29,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":30,"methods":1,"results":1},"count":32,"evidence_window":{"end":"2026-09-11","start":"2024-02-03"},"retrieval_snapshot":"2026-10-28T13:08:59.010182Z","timeline":[{"count":1,"week":"2024-W05"},{"count":1,"week":"2024-W43"},{"count":1,"week":"2024-W44"},{"count":1,"week":"2024-W45"},{"count":1,"week":"2024-W46"},{"count":1,"week":"2026-W21"},{"count":21,"week":"2026-W22"},{"count":1,"week":"2026-W24"},{"count":1,"week":"2026-W30"},{"count":1,"week":"2026-W37"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT04222972:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04222972:results","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04222972:context","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04222972:sap:1","quote_policy":"short_quote_link_out"},{"id":"pubmed:35973665","quote_policy":"short_quote_link_out"},{"id":"openfda:16edd46e-28b8-f06d-e063-6394a90ae31b:20251230","quote_policy":"short_quote_link_out"},{"id":"openfda:4c89cedc-e48b-445c-ad05-54dbe60e4fb0:20260721","quote_policy":"short_quote_link_out"},{"id":"openfda:508496cb-3441-46b3-a4fe-e0d440e6adc6:20260624","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-pwbuf4hieo24wlhs7d7fmfhl-3mmtrzv47xw22","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3mmqstatdkf2z","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1215254028508004355:3105d9a9-1c1c-4d94-a0a3-a262345e24ee","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1215603972385333248:49f07ace-da74-427a-8e93-14e93fdee4af","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1753742982644224372:d7f27d6a-deb7-4259-9b5d-b130236bc898","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1849902004073607272:f1b0487f-3ec7-4375-8c99-ff445ca42510","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1852180533410750905:965a5083-5480-4999-b961-e9d3e7892791","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1854912264995770441:e8bab731-82a1-4afb-9ed1-b6003049660e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1856725492646465888:496a3fed-0eda-4d06-b774-77bb65bea605","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2000653269593628987:5924583a-ab8f-4844-950e-67c1537a42ff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2048401716651991428:7c3a07a3-95db-46cb-9340-83dca115533a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056490345181880551:0a8b840c-7d65-4bb8-ac72-5c76f87fb28d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2057615031949562140:aeb8e797-56e8-4cc2-93b7-0138e760c0fa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2057630852482261213:76cb24be-a231-4544-bb9f-277428e94a83","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2057850459592032272:95540dd7-99a7-4e62-ba5d-4eaff312b7ea","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2059654965858123943:782f7cc5-53df-4e95-9a29-36520cbb42a5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060217653432553813:3931231b-a899-4a1d-9b4a-0a5cd6639d22","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060293263639314765:1409d2ad-7a72-4fe5-a748-809dbd2d1a72","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060302355308941780:e6553e49-24b5-4e36-b0fb-34779be2f079","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060444202190725582:a59c3ab3-af5d-47a7-9d66-8d13fa746a84","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060444273586143330:4902a8d2-62de-4ff9-bd66-787a08705e0c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060444607079469163:01ce8db3-4f2a-4924-b26d-3da8f9846670","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060444704345616474:b2a3abc1-683d-41de-b361-f2d1165cd86e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060444768987980137:dbb248cf-b885-4449-9e22-4a452a6faf96","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060444787975843921:93f0c67f-7208-4835-bb3e-2dc9a5a66cc7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060444791544881205:dde3b3fe-018b-41fa-8bf7-0242a4743055","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060445066385395930:4d50ee18-2abb-436a-8dd4-1cd41a23ef95","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060445487216427318:25051f0e-dee5-4b0c-ab25-e5f1f6985449","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060445830419497261:3c0f3ee0-8484-4702-949f-ecc17fa524eb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060446518860013775:3b54f388-445e-4d0a-898d-06b5768369c8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060448771582857420:75cc8370-9340-49ff-bed6-fc2dd352a2da","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060449508345995676:b18236dd-f06e-4391-830c-f54219ab7eb3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060453191842431057:9bc5ecf0-551b-4fb7-8219-17430a35c94e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060480331291975966:f1df9889-eb38-4144-977c-6657db857686","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060493192143794528:21fbe85a-0792-464f-a963-0da558a8d05f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060525857005810118:46b04592-5d5a-407b-8c12-53e480ba006d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060526941665693930:0cf4e8fc-9c27-4950-82a4-462808c14aad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060527741313642606:a5494e0c-3a18-4676-810c-4e63161302d0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060528882982224330:59a69f0b-31c1-45dc-b17f-169f271f6802","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060671979183624373:01fa887d-0b98-45d6-be2e-26bb4381a72a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060696942225621050:1608634d-ec9a-42c8-81e7-0a89659f9b71","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060753497646358551:35712481-398d-4ca9-8982-24e4abb71314","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060809326655369636:2900cb08-2de6-4c4d-ad65-e460fbf0b9f8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060866135940051323:bc4950ff-e52f-4fac-8ef2-a7b573605995","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061066916333039788:fd34af1d-3282-4832-ad84-5417c1932b9b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061123276563267982:ace9818c-1f48-4349-9b12-8f7c2a5c25fe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2062518993634623575:837e1871-355b-436e-972a-9012d3fef991","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2064260855865229336:649c7fd2-3029-40d7-86d3-78966c67daef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2065803299933065396:b8df881d-82ef-4113-8916-f36868150411","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2073385592809754802:073e084b-b8f2-4144-b0de-71b194829d1e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2079612486446178762:27efd0e1-65e7-4120-996d-d3ebe153ea6c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098210574714953930:c7173cc9-cf8a-47ec-b5a5-65f3e92f8dfa","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:aD-gtC_qobA","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":2,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":50,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":53},"count":53,"evidence_window":{"end":"2026-09-11","start":"2020-01-09"},"retrieval_snapshot":"2026-10-28T13:08:59.010182Z","timeline":[{"count":2,"week":"2020-W02"},{"count":1,"week":"2024-W05"},{"count":1,"week":"2024-W43"},{"count":1,"week":"2024-W44"},{"count":1,"week":"2024-W45"},{"count":1,"week":"2024-W46"},{"count":1,"week":"2025-W51"},{"count":1,"week":"2026-W17"},{"count":4,"week":"2026-W21"},{"count":34,"week":"2026-W22"},{"count":1,"week":"2026-W23"},{"count":2,"week":"2026-W24"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W30"},{"count":1,"week":"2026-W37"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: pralsetinib","status":"unmapped"},{"brand_names":["Paraplatin"],"label":"carboplatin","slug":"carboplatin"},{"brand_names":["Platinol"],"label":"cisplatin","slug":"cisplatin"},{"brand_names":["Alimta"],"label":"pemetrexed","slug":"pemetrexed"},{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"},{"brand_names":["Gemzar"],"label":"gemcitabine","slug":"gemcitabine"},{"brand_names":["Taxol"],"label":"paclitaxel","slug":"paclitaxel"},{"brand_names":["Abraxane"],"label":"nab-paclitaxel","slug":"nab-paclitaxel"}],"indications":[{"reason":"Unmapped registry condition: RET-fusion Non Small Cell Lung Cancer","status":"unmapped"},{"reason":"Unmapped registry condition: Lung Neoplasm","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"},{"reason":"Unmapped registry condition: Respiratory Tract Neoplasms","status":"unmapped"},{"reason":"Unmapped registry condition: Thoracic Neoplasms","status":"unmapped"},{"reason":"Unmapped registry condition: Neoplasms by Site","status":"unmapped"},{"reason":"Unmapped registry condition: Neoplasms","status":"unmapped"},{"reason":"Unmapped registry condition: Lung Diseases","status":"unmapped"},{"reason":"Unmapped registry condition: Respiratory Tract Disease","status":"unmapped"},{"reason":"Unmapped registry condition: Carcinoma, Bronchogenic","status":"unmapped"},{"reason":"Unmapped registry condition: Bronchial Diseases","status":"unmapped"},{"reason":"Unmapped registry condition: Head and Neck Neoplasms","status":"unmapped"},{"reason":"Unmapped registry condition: Adenocarcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Carcinoma","status":"unmapped"},{"reason":"Unmapped registry condition: Neoplasms by Histologic Type","status":"unmapped"},{"reason":"Unmapped registry condition: Neoplasms, Germ Cell and Embryonal","status":"unmapped"},{"reason":"Unmapped registry condition: Neoplasms, Nerve Tissue","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"AcceleRET-Lung","aliases":["AcceleRET-Lung","A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer"],"brief_title":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["RET-fusion Non Small Cell Lung Cancer","Lung Neoplasm","Carcinoma, Non-Small-Cell Lung","Respiratory Tract Neoplasms","Thoracic Neoplasms","Neoplasms by Site","Neoplasms","Lung Diseases","Respiratory Tract Disease","Carcinoma, Bronchogenic","Bronchial Diseases","Head and Neck Neoplasms","Adenocarcinoma","Carcinoma","Neoplasms by Histologic Type","Neoplasms, Germ Cell and Embryonal","Neoplasms, Nerve Tissue"],"enrollment":{"count":223,"type":"ACTUAL"},"interventions":[{"name":"Pralsetinib","synonyms":["BLU-667"],"type":"DRUG"},{"name":"Carboplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Cisplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Pemetrexed","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Pembrolizumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Gemcitabine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Paclitaxel","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Nab-Paclitaxel","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT04222972","official_title":"A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer","overall_status":"TERMINATED","phase":["PHASE3"],"primary_completion_date":{"date":"2025-01-27","type":"ACTUAL"},"primary_endpoints":[{"description":"PFS was defined as the time from randomization to the date of first documented PD as determined by the investigator with the use of Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD at prior timepoints, including baseline. In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of at least 5 millimeters (mm). Kaplan-Meier (K-M) method was used to estimate median PFS. 95% CI for median was computed using the method of Brookmeyer and Crowley.","measure":"Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS)","timeFrame":"Up to approximately 50 months"}],"registry_last_updated":"2026-03-05","registry_url":"https://clinicaltrials.gov/study/NCT04222972","short_name":"AcceleRET-Lung","short_name_basis":"registry_acronym","sponsor":"Hoffmann-La Roche","start_date":{"date":"2020-07-24","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"BO42864","type":"sponsor_study_id"},{"id":"2019-002463-10","type":"eudract_number"},{"domain":"CT.Gov","id":"BLU-667-2303","type":"registry"},{"domain":"EU CT number","id":"2023-505035-12-00","type":"other"}],"study_type":"INTERVENTIONAL"}}}